Table 1.
Cohort characteristics at baseline
| Study cohort (n = 30) | |
|---|---|
| Femalea | 28 (93.3) |
| Ageb | 32.8 (8.4) |
| Disease duration (months)c | 3 (2–7.5) |
| CSF opening pressure (cmCSF)c | 33.0 (26.9–35.3) |
| Volume of CSF drained (ml)d | 29 (10–40) |
| BMI (kg/m2)c | 34.8 (30.9–40.9) |
| IIH-WOPa | 5 (16.7) |
| Visual disturbancesa | 22 (73.3) |
| Tinnitusa | 15 (50.0) |
| Therapy after diagnostic LP | |
| Acetazolamidea | 29 (96.7) |
| Median acetazolamide dosage (mg)c | 1,000 (500–1,000) |
| Topiramatea | 1 (3.3) |
| Topiramate dosage (mg) | 50 |
| Headache | |
| Headache presencea | 20 (66.7) |
| MHDc | 13.5 (10–28) |
| Chronic headachea | 12 (40.0) |
| Median headache severity (NRS)b | 5 (3.8–6) |
| Peak headache severity (NRS)c | 8.5 (7–10) |
| HIT-6b | 55.5 (10.8) |
| Ophthalmological parameters | |
| Frisén-Scalec | 2 (1–3) |
| Visual acuity of worse eye (logMAR)c | 0.00 (-0.08, 0.00) |
| Decreased visual acuitya | 2 (6.7) |
| Visual field mean deviation of worse eye (dB)c | -1.84 (-5.27, -0.57) |
| Abnormal visual fielda | 14 (46.7) |
| pRNFL thickness of the worse eye (µm)c | 145.5 (97.8–221.5) |
| GCL volume of the worse eye (mm3)c | 1.05 (1.0-1.16) |
| Presence of a bat sign in echographya | 28 (93.3) |
| Abnormal AONSDa | 29 (96.7) |
| AONSD of the worse eyeb | 5.85 (0.75) |
aNumber (percentage), bMean (standard deviation), cMedian (interquartile range), dMedian (range)
AONSD: arachnoid optic nerve sheath diameter, BMI: body mass index, CSF: cerebrospinal fluid, GCL: ganglion cell layer, IIH-WOP: idiopathic intracranial hypertension without papilledema, LP: lumbar puncture, MHD: monthly headache days, NRS: Numeric Rating Scale, pRNFL: peripapillary retinal nerve fiber layer